Screener
Capricor Therapeutics CAPR Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Capricor Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:StockOptionPlanExpense.
The source filing: Capricor Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 5:20 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-060382
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Net loss | $(33,941,345) | $(24,391,594) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 534,670 | 405,450 |
| Stock-based compensation | 5,918,055 | 5,481,938 |
| Restricted stock awards granted | — | 257,461 |
| Amortization/accretion of note premiums/discounts | (358,625) | — |
| Changes in lease liabilities | 641,285 | (16,844) |
| Other | (6,591) | 150,673 |
Item 1. Financial Statements.
FAQ
- What is Capricor Therapeutics's stock-based comp?
- Capricor Therapeutics (CAPR) reported stock-based comp of $5.92M in Q1 2026.
- How has Capricor Therapeutics's stock-based comp changed year-over-year?
- Capricor Therapeutics's stock-based comp increased by 8.0% year-over-year, from $5.48M to $5.92M.
- What is the long-term trend for Capricor Therapeutics's stock-based comp?
- Over 4 years (2021 to 2025), Capricor Therapeutics's stock-based comp has grown at a 54.7% compound annual growth rate (CAGR), from $2.97M to $16.97M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Capricor Therapeutics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude